We are excited to announce that Biocytogen will exhibit at the 2nd Immuno-Oncology & Biomarker Summit from October 19 - 20 in Camden, NJ. This is a fantastic opportunity to exchange research insights, discuss clinical applications, and build connections across the oncology community. Come meet our team at booth #1 to explore target-humanized mouse models supporting translational immuno-oncology research, from biomarker and target evaluation to in vivo efficacy and safety assessment.
What is the 2nd Immuno-Oncology and Biomarker Summit?
The 2nd Immuno-Oncology & Biomarker Summit will bring researchers, clinicians, and industry professionals together to examine advances in cancer therapy and precision medicine. Organized by Veridon Global, the event will cover emerging immunotherapies, antibody and cell therapies, and approaches to treatment resistance. The program will also cover how biomarkers, liquid biopsies, and AI-assisted analysis can guide patient selection and treatment decisions.
Event Overview
Date: October 19th - 20th, 2026
Venue: Hilton Garden Inn Camden Waterfront Philadelphia, 1 Penn St, Camden, NJ 08102
Booth: 1
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
